NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $37.19 -1.01 (-2.64%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$36.49 -0.70 (-1.88%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edgewise Therapeutics Stock (NASDAQ:EWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edgewise Therapeutics alerts:Sign Up Key Stats Today's Range$36.70▼$38.2850-Day Range$36.28▼$46.9452-Week Range$14.68▼$48.51Volume1.31 million shsAverage Volume1.69 million shsMarket Capitalization$4.04 billionP/E RatioN/ADividend YieldN/APrice Target$51.33Consensus RatingModerate Buy Company Overview Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small-molecule therapies for severe neuromuscular and cardiovascular diseases. The company’s research is centered on muscle biology, with the goal of developing treatments that address the underlying mechanisms of muscle damage and dysfunction. Edgewise’s lead investigational product is sevasemten, formerly known as EDG-5506, a selective fast skeletal muscle myosin inhibitor being developed for dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company is also developing EDG-7500, an investigational cardiac myosin modulator intended for the treatment of hypertrophic cardiomyopathy and other cardiovascular conditions. Founded in 2017 and headquartered in Boulder, Colorado, Edgewise conducts research and clinical development activities through collaborations and clinical trials in the United States and other regions. Kevin Koch serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Edgewise Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreEWTX MarketRank™: 2.607086197775 of 5 starsEdgewise Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 474th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEdgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEdgewise Therapeutics has a consensus price target of $51.33, representing about 38.0% upside from its current price of $37.19.Amount of Analyst CoverageEdgewise Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edgewise Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Edgewise Therapeutics are expected to grow in the coming year, from ($2.09) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -20.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -20.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 7.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.13% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 17.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.18 News SentimentEdgewise Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Edgewise Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,675,529.00 in company stock.Percentage Held by Insiders21.30% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsEdgewise Therapeutics has minimal institutional ownership at this time.Read more about Edgewise Therapeutics' insider trading history. Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EWTX Stock News HeadlinesWilliam Blar Initiates Coverage on Edgewise Therapeutics With Outperform RatingOctober 17 at 4:09 PM | finance.yahoo.comDoes Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?October 15 at 8:25 AM | finance.yahoo.comThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.October 18 at 1:00 AM | Behind the Markets (Ad)Edgewise’s EQUINOX-HFpEF Trial: A Fresh Catalyst in the Heart Failure PipelineOctober 13, 2026 | tipranks.comEdgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure DrugOctober 8, 2026 | finance.yahoo.comEdgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock DownOctober 8, 2026 | rttnews.comEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400October 8, 2026 | prnewswire.comEdgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?October 2, 2026 | finance.yahoo.comSee More Headlines EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $24.82 on January 1st, 2026. Since then, EWTX shares have increased by 49.8% and is now trading at $37.19. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.06. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $165 million in an IPO on Friday, March 26th 2021. The company issued 11,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional investors include Assenagon Asset Management S.A. (0.68%) and GAMMA Investing LLC. Insiders that own company stock include Orbimed Advisors Llc, Peter A Thompson, R Michael Carruthers, Kevin Koch, Alan J Russell, Jonathan C Fox, Badreddin Edris, John R Moore, Behrad Derakhshan, Joanne M Donovan and Marc Semigran. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edgewise Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Cytokinetics (CYTK), Micron Technology (MU), Plug Power (PLUG), Super Micro Computer (SMCI) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/06/2026Today10/18/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EWTX's financial health is in the Green zone, according to TradeSmith. EWTX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EWTX CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees127Year Founded1962Price Target and Rating Average Price Target for Edgewise Therapeutics$51.33 High Price Target$66.00 Low Price Target$25.00 Potential Upside/Downside+38.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-39.01% Return on Assets-36.96% Debt Debt-to-Equity RatioN/A Current Ratio16.24 Quick Ratio16.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book7.54Miscellaneous Outstanding Shares108,600,000Free Float85,471,000Market Cap$4.04 billion OptionableOptionable Beta0.35 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:EWTX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
